Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

20.88 +1.15 (+5.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
Via Benzinga
Could an FDA Approval Send This Stock Flying?
Is now the time to load up on this struggling stock? 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
Travere Therapeutics's Return On Capital Employed Overview
Via Benzinga
Why Travere Therapeutics Stock Bolted Higher This Week
A high-value regulatory approval lit a fire underneath the biotech's shares this week. 
Via The Motley Fool
Travere Therapeutics's Earnings Outlook
Via Benzinga
What 10 Analyst Ratings Have To Say About Travere Therapeutics
Via Benzinga
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
The Latest Analyst Ratings for Travere Therapeutics
Via Benzinga
4 Analysts Have This to Say About Travere Therapeutics
Via Benzinga
Where Travere Therapeutics Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Recap: Travere Therapeutics Q3 Earnings
Travere Therapeutics (NASDAQ:TVTX) reported its Q3 earnings results on Thursday, October 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA
Via Benzinga
The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February
These two growth stocks might deliver enormous gains for shareholders this month. 
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday saw 196 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's trading, 160 companies set new 52-week lows. 
Via Benzinga
Travere Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter. 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
Earnings Outlook For Travere Therapeutics
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
121 Stocks That Hit Their 52-Week Low
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.